We showed that high JMJD1B or JMJD1C expression indicates poor prognosis in ovarian cancer patients, which has also been reported for breast cancer patients [68] and therefore corroborates a pro-tumorigenic role of these epigenetic regulators. This evidence concerns the gene KDM3B and ovarian cancer.